PLEASANTON, Calif., Jan. 6 /PRNewswire-FirstCall/ -- Thoratec Corporation (Nasdaq: THOR), a world leader in device-based mechanical circulatory support therapies to save, support and restore failing hearts, said today that it will be participating in the 27th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14.
Gary Burbach, president and chief executive officer, will provide an update on the company, beginning at 9 a.m., Pacific Standard Time (12 p.m. Eastern Standard Time).
The presentation will be available through the conference website at http://metameetings.com/webcasts/jpmorgan/healthcare09/directlink?ticker=THOR or on the company's website at http://www.thoratec.com.
Thoratec is a world leader in therapies to address advanced-stage heart failure. The company's product lines include the Thoratec(R) VAD (Ventricular Assist Device) and HeartMate(R) LVAS (Left Ventricular Assist System) with nearly 12,000 devices implanted in patients suffering from heart failure. Additionally, its International Technidyne Corporation (ITC) division supplies point-of-care blood testing and skin incision products. Thoratec is headquartered in Pleasanton, California. For more information, visit the company's web sites at http://www.thoratec.com or http://www.itcmed.com.
|SOURCE Thoratec Corporation|
Copyright©2009 PR Newswire.
All rights reserved